about
Is AMH a regulator of follicular atresia?Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in womenAn appraisal of barrier agents in the reduction of adhesion formation following surgery.Vitamin D Decreases Serum VEGF Correlating with Clinical Improvement in Vitamin D-Deficient Women with PCOS: A Randomized Placebo-Controlled Trial.Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulationAssisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011.Variations in serum müllerian inhibiting substance between white, black, and Hispanic women.Changes in plasma müllerian-inhibiting substance and brain-derived neurotrophic factor after chemotherapy in premenopausal womenImpact of CD4+ lymphocytes and HIV infection on Anti-Müllerian Hormone levels in a large cohort of HIV-infected and HIV-uninfected womenKnowledge of ovarian reserve and reproductive choicesCirculating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study.Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates.Potential mechanisms for racial and ethnic differences in antimüllerian hormone and ovarian reserve.Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulationInduction of ovulation for IVF and its effect on the luteal phase.Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone.Putting 'family' back in family planning.Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis.The emerging role of angiogenic factor dysregulation in the pathogenesis of polycystic ovarian syndrome.Personalized prediction of live birth: Are we there yet?Assessing ovarian response: antral follicle count versus anti-Müllerian hormone.Society for Assisted Reproductive Technology and assisted reproductive technology in the United States: a 2016 update.Ovarian reserve testing: a user's guide.Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology.The impact of hydrosalpinx on successful pregnancy in tubal factor infertility treated by in vitro fertilization.Brain-derived neurotrophic factor: a novel human ovarian follicular protein.Erratum: Biosimilar FSH preparations- are they identical twins or just siblings?Activin A stimulates meiotic maturation of human oocytes and modulates granulosa cell steroidogenesis in vitro.Biosimilar FSH preparations- are they identical twins or just siblings?Alpha-fetoprotein as a tool to distinguish amniotic fluid from urine, vaginal discharge, and semen.Flow cytometric analysis of deoxyribonucleic acid in human granulosa cells as a function of chronological age and ovulation induction regimen.Blood exposure in single versus double gloving during pelvic surgery.But isn't antimüllerian hormone still better than follicle-stimulating hormone?Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles.Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles.Parameters of hypothalamic aging.Trends of racial disparities in assisted reproductive technology outcomes in black women compared with white women: Society for Assisted Reproductive Technology 1999 and 2000 vs. 2004-2006.Cultural factors contributing to health care disparities among patients with infertility in Midwestern United States.Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.
P50
Q27006736-1890425A-17E1-4E18-B37A-B5A5E0E170B8Q30439646-4CBAC1A8-4E7B-4216-9A08-30462F8DC365Q33564952-39A970EC-4B4C-4E6A-9723-94DBB5795944Q33616612-AF76D665-8F74-4A4D-BA86-FBF88BD0F593Q34116423-9041D591-A143-4015-BA0D-C6CE63E0DC92Q34288116-8D1B3A70-94C6-4AA3-B88B-C4BC6E8A04C7Q34568747-E1627BA0-9125-4B8C-90B2-BFECF54E6DC6Q34618818-F1A2B8C9-D5DB-4D2D-A9DE-D2706ACD1DCAQ35070210-57104E6E-56EC-4D69-98AD-28DCC1680AD0Q35186925-EC806566-2012-4827-A7D5-D6B488B0ABEBQ36074219-76F93572-EAEC-4925-AFBA-690E4B9388B6Q36579307-1F3E5882-4FC9-4403-889D-A2E101254F35Q37379906-7F7B1933-1A0C-4B7A-97AF-131CD2F33352Q37493521-1566E746-D7F5-4981-9E4D-12DEF742477AQ37768721-C89FE09F-D782-415D-AC00-E824CBC8CC2CQ38095280-D057C8FB-8993-430C-A51D-5218F5037212Q38269185-65662373-3F59-4244-997E-635B5F3D61C5Q38275691-6BF8C4FE-F234-4B25-87A0-72B708FD6918Q38513472-2E5F6D80-2A11-4B46-BDB1-887E0FB55B5DQ38518016-6AAE0E7B-F9E8-4950-9DEB-5F0FE65A288EQ38568662-3D7CB84F-CD2A-471F-9E1C-1606C238DE63Q38865278-9D418772-532C-4B79-83B3-AE1D013901AAQ39149826-67F3BE9D-AE00-477F-A09F-E796FF318DDDQ40394248-F449F888-DB51-4DD2-8DB7-BC137852CAB6Q41416189-E17FE86E-E81F-4BF3-805C-7BBE5E539228Q42166268-EB9E39E6-2FE3-444A-9B10-693B08B11A54Q42394843-C1BBC00A-4193-49A6-BF6A-6D07FF37245AQ42465118-E1331D4D-8EC5-43FC-B591-50F1D3F8F626Q42710024-8570AE10-583D-4D2C-9707-43C851B1F9A8Q43328015-89136047-5918-4637-A70F-2EE93595B524Q43636572-BF2DDC55-A20D-4D15-9888-3030329AEB63Q43685620-C27C10E1-1B40-4C46-85C4-FEDF01604DE4Q43770064-7CB5EAF2-2CFD-4174-A9DC-A7649D115969Q43826158-655E9E40-8629-41AF-B4B0-C5426BB9C0A6Q43901202-E46BD070-39DB-49C5-8248-2BC324872E2BQ44117624-17C0B530-29FD-4EC0-B95B-B57F5DBA78F5Q44439630-2DD75713-E688-49B0-83B2-70B063511BADQ44610378-B9578EE6-0712-4BF4-85F7-08534A359E71Q45143966-346B026A-3247-4249-B7B7-87300C70048DQ45225993-0599DB82-A68A-47A0-99A9-0F92E3C57287
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
David B Seifer
@nl
David B Seifer
@sl
David B. Seifer
@en
David B. Seifer
@es
type
label
David B Seifer
@nl
David B Seifer
@sl
David B. Seifer
@en
David B. Seifer
@es
prefLabel
David B Seifer
@nl
David B Seifer
@sl
David B. Seifer
@en
David B. Seifer
@es
P1006
P214
P244
P1006
P106
P1153
7005207329
P21
P214
P244
P31
P496
0000-0003-3950-9341
P735
P7859
lccn-n96801962